FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill

LONDON, Feb 6 (Reuters) - After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.